Genetic analysis of DCCs revealed that DCCs from HR+ breast cancer progressing to manifest metastasis often acquired PIK3CA mutations, possibly because the activated PI3K/AKT pathway rendered mammary epithelial cells independent of IL-6 trans-signaling. The gene discussed is IL6; the disease is breast carcinoma.